Imatinib is a tyrosine kinase inhibitor targeting Abl, c-kit and platelet-derived growth factor receptor (PDGFR) that is currently in a phase II trial in combination with paclitaxel for serous adenocarcinoma with high expression of Abl and PDGFR. Here, PDGFRB is linked to serous adenocarcinoma.